Consumer Genomics Market Size, Share & Trends Analysis Report By Application (Genetic Relatedness, Ancestry, Diagnostics, Sports Nutrition & Health), By Region (North America, Europe), And Segment Forecasts, 2023 - 2030
Consumer Genomics Market Growth & Trends
The global consumer genomics market size is expected to reach USD 7.20 billion by 2030, registering a CAGR of 24.8% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rise in consumer and physician interest in direct-to-consumer (DTC) kits, coupled with a subsequent increase in the sales of DNA test kits, and the growing trend of personalized genomics, are expected to drive market expansion over the forecast period. The most common tests utilize a small number of genetic changes to predict certain health characteristics, reveal common traits, and provide ancestry hints. With the expansion of the variety of health information these tests can uncover, an increasing number of companies are offering genetic testing directly to consumers.
The surge in consumer and physician interest in DTC kits, technological improvements, an increase in consumer genomics applications, supportive governmental policies, and the growing trend of personalized genomics are the primary drivers of market expansion. For instance, according to a ScienceDirect article, direct-to-consumer (DTC) tests became more prevalent in 2022 as they could be purchased without a doctor's prescription.
The COVID-19 pandemichas heightened people's concerns about their health, potentially encouraging them to explore novel and cutting-edge methods like consumer genomics. Therefore, the market is expected to maintain its considerable growth rate over the forecast period due to the increasing efforts in DNA-based research and development, as well as bioinformatics, aimed at creating diagnostic tools and efficient therapies for COVID-19.
Consumer Genomics Market Report Highlights
- The genetic relatedness segment accounted for the largest revenue share in 2022 due to its involvement in the most common type of paternal testing
- The dissolving microneedle segment is expected to grow at the fastest rate during the forecast period since it requires only one step, and the microneedle does not need to be removed after insertion
- Companies such as FamilyTree DNA; AncestryDNA; 23andMe, Inc.; MyHeritage, and others offer several paternal and maternal tests. These tests provide information about genetic relations and ancestry at an affordable cost
- Asia Pacific is anticipated to experience the fastest CAGR over the forecast period due to the increasing awareness related to DTC genetics and the availability of funding for long-term research initiatives
- Chapter 1. Methodology and Scope
- 1.1. Market Segment & Scope
- 1.1.1. Application
- 1.1.2. Regional Scope
- 1.1.3. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.4. Information Or Data Analysis
- 1.4.1. Data Analysis Model
- 1.5. Market Scope & Segment Definition
- 1.6. Market Model
- 1.6.1. Market Study, By Company Market Share
- 1.6.2. Regional Analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rise in interest of consumers & physicians in DTC kits & consequent rise in sales of DNA test kits
- 3.2.1.2. Increase in access to DTC services due to reducing cost of genotyping
- 3.2.1.3. Expansion in applications of DTC genetics
- 3.2.1.3.1. Health testing
- 3.2.1.3.2. Ancestry
- 3.2.1.3.3. Genetic relatedness
- 3.2.1.4. Significant investments & initiatives by companies to maintain their competitive edge in the market
- 3.2.1.5. Growing trend of personalized genomics
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Ethical and clinical issues pertaining to the use of DTC products & personalized treatment
- 3.2.2.2. Misleading results create challenges in adoption of home-based genetic tests
- 3.2.2.3. Regulatory challenges pertaining to the use of DTC genetic tests
- 3.3. Industry Analysis Tools
- 3.3.1. Porter’s Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- Chapter 4. Consumer Genomics Application Business Analysis
- 4.1. Consumer Genomics Market: Application Movement Analysis
- 4.2. Genetic Relatedness
- 4.2.1. Genetic Relatedness Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3. Ancestry
- 4.3.1. Ancestry Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Lifestyle, Wellness, & Nutrition
- 4.4.1. Lifestyle, Wellness, & Nutrition Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Diagnostics
- 4.5.1. Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Sports Nutrition & Health
- 4.6.1. Sports Nutrition & Health Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Reproductive Health
- 4.7.1. Reproductive Health Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.8. Personalized medicine & Pharmacogenetic testing
- 4.8.1. Personalized medicine & Pharmacogenetic testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.9. Others
- 4.9.1. Other Application Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 5. Regional Business Analysis
- 5.1. Consumer Genomics Market: Regional Market Snapshot
- 5.2. North America
- 5.2.1. North America Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.2.2. U.S.
- 5.2.2.1. Key Country Dynamics
- 5.2.2.2. Target Disease Prevalence
- 5.2.2.3. Competitive Scenario
- 5.2.2.4. Regulatory Framework
- 5.2.2.5. U.S. Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.2.3. Canada
- 5.2.3.1. Key Country Dynamics
- 5.2.3.2. Target Disease Prevalence
- 5.2.3.3. Competitive Scenario
- 5.2.3.4. Regulatory Framework
- 5.2.3.5. Canada Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3. Europe
- 5.3.1. Europe Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.2. UK
- 5.3.2.1. Key Country Dynamics
- 5.3.2.2. Target Disease Prevalence
- 5.3.2.3. Competitive Scenario
- 5.3.2.4. Regulatory Framework
- 5.3.2.5. UK Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.3. Germany
- 5.3.3.1. Key Country Dynamics
- 5.3.3.2. Target Disease Prevalence
- 5.3.3.3. Competitive Scenario
- 5.3.3.4. Regulatory Framework
- 5.3.3.5. Germany Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.4. France
- 5.3.4.1. Key Country Dynamics
- 5.3.4.2. Target Disease Prevalence
- 5.3.4.3. Competitive Scenario
- 5.3.4.4. Regulatory Framework
- 5.3.4.5. France Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.5. Italy
- 5.3.5.1. Key Country Dynamics
- 5.3.5.2. Target Disease Prevalence
- 5.3.5.3. Competitive Scenario
- 5.3.5.4. Regulatory Framework
- 5.3.5.5. Italy Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.6. Spain
- 5.3.6.1. Key Country Dynamics
- 5.3.6.2. Target Disease Prevalence
- 5.3.6.3. Competitive Scenario
- 5.3.6.4. Regulatory Framework
- 5.3.6.5. Spain Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.7. Denmark
- 5.3.7.1. Key Country Dynamics
- 5.3.7.2. Target Disease Prevalence
- 5.3.7.3. Competitive Scenario
- 5.3.7.4. Regulatory Framework
- 5.3.7.5. Denmark Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.8. Sweden
- 5.3.8.1. Key Country Dynamics
- 5.3.8.2. Target Disease Prevalence
- 5.3.8.3. Competitive Scenario
- 5.3.8.4. Regulatory Framework
- 5.3.8.5. Sweden Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.3.9. Norway
- 5.3.9.1. Key Country Dynamics
- 5.3.9.2. Target Disease Prevalence
- 5.3.9.3. Competitive Scenario
- 5.3.9.4. Regulatory Framework
- 5.3.9.5. Norway Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4. Asia Pacific
- 5.4.1. Asia Pacific Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.2. Japan
- 5.4.2.1. Key Country Dynamics
- 5.4.2.2. Target Disease Prevalence
- 5.4.2.3. Competitive Scenario
- 5.4.2.4. Regulatory Framework
- 5.4.2.5. Japan Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.3. China
- 5.4.3.1. Key Country Dynamics
- 5.4.3.2. Target Disease Prevalence
- 5.4.3.3. Competitive Scenario
- 5.4.3.4. Regulatory Framework
- 5.4.3.5. China Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.4. India
- 5.4.4.1. Key Country Dynamics
- 5.4.4.2. Target Disease Prevalence
- 5.4.4.3. Competitive Scenario
- 5.4.4.4. Regulatory Framework
- 5.4.4.5. India Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.5. Australia
- 5.4.5.1. Key Country Dynamics
- 5.4.5.2. Target Disease Prevalence
- 5.4.5.3. Competitive Scenario
- 5.4.5.4. Regulatory Framework
- 5.4.5.5. Australia Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.6. Switzerland
- 5.4.6.1. Key Country Dynamics
- 5.4.6.2. Target Disease Prevalence
- 5.4.6.3. Competitive Scenario
- 5.4.6.4. Regulatory Framework
- 5.4.6.5. Switzerland Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.7. Thailand
- 5.4.7.1. Key Country Dynamics
- 5.4.7.2. Target Disease Prevalence
- 5.4.7.3. Competitive Scenario
- 5.4.7.4. Regulatory Framework
- 5.4.7.5. Thailand Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.4.8. South Korea
- 5.4.8.1. Key Country Dynamics
- 5.4.8.2. Target Disease Prevalence
- 5.4.8.3. Competitive Scenario
- 5.4.8.4. Regulatory Framework
- 5.4.8.5. South Korea Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.5. Latin America
- 5.5.1. Latin America Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.5.2. Brazil
- 5.5.2.1. Key Country Dynamics
- 5.5.2.2. Target Disease Prevalence
- 5.5.2.3. Competitive Scenario
- 5.5.2.4. Regulatory Framework
- 5.5.2.5. Brazil Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.5.3. Mexico
- 5.5.3.1. Key Country Dynamics
- 5.5.3.2. Target Disease Prevalence
- 5.5.3.3. Competitive Scenario
- 5.5.3.4. Regulatory Framework
- 5.5.3.5. Mexico Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.5.4. Argentina
- 5.5.4.1. Key Country Dynamics
- 5.5.4.2. Target Disease Prevalence
- 5.5.4.3. Competitive Scenario
- 5.5.4.4. Regulatory Framework
- 5.5.4.5. Argentina Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.6. MEA
- 5.6.1. MEA Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.6.2. South Africa
- 5.6.2.1. Key Country Dynamics
- 5.6.2.2. Target Disease Prevalence
- 5.6.2.3. Competitive Scenario
- 5.6.2.4. Regulatory Framework
- 5.6.2.5. South Africa Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.6.3. Saudi Arabia
- 5.6.3.1. Key Country Dynamics
- 5.6.3.2. Target Disease Prevalence
- 5.6.3.3. Competitive Scenario
- 5.6.3.4. Regulatory Framework
- 5.6.3.5. Saudi Arabia Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.6.4. UAE
- 5.6.4.1. Key Country Dynamics
- 5.6.4.2. Target Disease Prevalence
- 5.6.4.3. Competitive Scenario
- 5.6.4.4. Regulatory Framework
- 5.6.4.5. UAE Consumer Genomics Market, 2018 - 2030 (USD Million)
- 5.6.5. Kuwait
- 5.6.5.1. Key Country Dynamics
- 5.6.5.2. Target Disease Prevalence
- 5.6.5.3. Competitive Scenario
- 5.6.5.4. Regulatory Framework
- 5.6.5.5. Kuwait Consumer Genomics Market, 2018 - 2030 (USD Million)
- Chapter 6. Competitive Landscape
- 6.1. Company Categorization
- 6.2. Strategy Mapping
- 6.3. Company Market Share Analysis, 2022
- 6.4. Company Profiles/Listing
- 6.4.1. Ancestry
- 6.4.1.1. Overview
- 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.1.3. Product Benchmarking
- 6.4.1.4. Strategic Initiatives
- 6.4.2. 23andMe, Inc.
- 6.4.2.1. Overview
- 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.2.3. Product Benchmarking
- 6.4.2.4. Strategic Initiatives
- 6.4.3. Gene by Gene, Ltd.
- 6.4.3.1. Overview
- 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.3.3. Product Benchmarking
- 6.4.3.4. Strategic Initiatives
- 6.4.4. Mapmygenome
- 6.4.4.1. Overview
- 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.4.3. Product Benchmarking
- 6.4.4.4. Strategic Initiatives
- 6.4.5. Color Health, Inc.
- 6.4.5.1. Overview
- 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.5.3. Product Benchmarking
- 6.4.5.4. Strategic Initiatives
- 6.4.6. Positive Biosciences, Ltd.
- 6.4.6.1. Overview
- 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.6.3. Product Benchmarking
- 6.4.6.4. Strategic Initiatives
- 6.4.7. Futura Genetics
- 6.4.7.1. Overview
- 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.7.3. Product Benchmarking
- 6.4.7.4. Strategic Initiatives
- 6.4.8. Helix OpCo LLC
- 6.4.8.1. Overview
- 6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.8.3. Product Benchmarking
- 6.4.8.4. Strategic Initiatives
- 6.4.9. MyHeritage Ltd.
- 6.4.9.1. Overview
- 6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.9.3. Product Benchmarking
- 6.4.9.4. Strategic Initiatives
- 6.4.10. Pathway Genomics
- 6.4.10.1. Overview
- 6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.10.3. Product Benchmarking
- 6.4.10.4. Strategic Initiatives
- 6.4.11. Veritas
- 6.4.11.1. Overview
- 6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.11.3. Product Benchmarking
- 6.4.11.4. Strategic Initiatives
- 6.4.12. Myriad Genetics, Inc.
- 6.4.12.1. Overview
- 6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.12.3. Product Benchmarking
- 6.4.12.4. Strategic Initiatives
- 6.4.13. Illumina, Inc.
- 6.4.13.1. Overview
- 6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.13.3. Product Benchmarking
- 6.4.13.4. Strategic Initiatives
- 6.4.14. Amgen, Inc.
- 6.4.14.1. Overview
- 6.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.14.3. Product Benchmarking
- 6.4.14.4. Strategic Initiatives
- 6.4.15. Xcode Life
- 6.4.15.1. Overview
- 6.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.15.3. Product Benchmarking
- 6.4.15.4. Strategic Initiatives
- 6.4.16. Diagnomics, Inc.
- 6.4.16.1. Overview
- 6.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.16.3. Product Benchmarking
- 6.4.16.4. Strategic Initiatives
- 6.4.17. Toolbox Genomics
- 6.4.17.1. Overview
- 6.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.4.17.3. Product Benchmarking
- 6.4.17.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook